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ABSTRACT 
Background & Aims: We assessed the diagnostic performance of magnetic resonance imaging 
(MRI) proton density fat fraction (PDFF) in grading hepatic steatosis and change in hepatic 
steatosis in adults with nonalcoholic steatohepatitis (NASH) in a multi-center study, using 
central histology as reference. 
 
Methods: We collected data from 113 adults with NASH participating in a multi-center, 
randomized, double-masked, placebo-controlled, phase 2b trial to compare the efficacy cross-
sectionally and longitudinally of obeticholic acid vs placebo. Hepatic steatosis was assessed at 
baseline and after 72 weeks of obeticholic acid or placebo by liver biopsy and MRI (scanners 
from different manufacturers, at 1.5T or 3T). We compared steatosis estimates by PDFF vs 
histology. Histologic steatosis grade was scored in consensus by a pathology committee. Cross-
validated receiver operating characteristic (ROC) analyses were performed. 
 
Results: At baseline, 34% of subjects had steatosis grade 0 or 1, 39% had steatosis grade 2, and 
27% had steatosis grade 3; corresponding mean PDFF values were 9.8%±3.7%, 18.1%±4.3%, 
and 30.1%±8.1%. PDFF classified steatosis grade 0–1 vs 2–3 with an area under the ROC curve 
(AUROC) of 0.95 (95% CI, 0.91–0.98), and grade 0–2 vs grade 3 steatosis with an AUROC of 
0.96 (95% CI, 0.93–0.99). PDFF cut-off values at 90% specificity were 16.3% for grades 2–3 
and 21.7% for grade 3, with corresponding sensitivities of 83% and 84%. After 72 weeks' of 
obeticholic vs. placebo, 42% of subjects had a reduced steatosis grade (mean reduction in PDFF 
from baseline of 7.4%±8.7%), 49% had no change in steatosis grade (mean increase in PDFF 
from baseline of 0.3%±6.3%), and 9% had an increased steatosis grade (mean increase in PDFF 
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from baseline of 7.7%±6.0%). PDFF change identified subjects with reduced steatosis grade with 
an AUROC of 0.81 (95% CI, 0.71–0.91) and increased steatosis grade with an AUROC of 0.81 
(95% CI, 0.63–0.99). A PDFF reduction of 5.15% identified subjects with reduced steatosis 
grade with 90% specificity and 58% sensitivity, whereas a PDFF increase of 5.6% identified 
those with increased steatosis grade with 90% specificity and 57% sensitivity. 
 
Conclusions: Based on data from a phase 2 randomized controlled trial of adults with NASH, 
PDFF estimated by MRI scanners of different field strength and at different sites, accurately 
classifies grades and changes in hepatic steatosis when histologic analysis of biopsies is used as a 
reference. 
 
KEY WORDS: FLINT, NAFLD, direct comparison, non-invasive 
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INTRODUCTION 
 Nonalcoholic fatty liver disease (NAFLD) is estimated to affect a billion people in the 
world today [1,2]. Reported population-based prevalence estimates of nonalcoholic 
steatohepatitis (NASH), in which hepatocellular injury and inflammation are present in addition 
to steatosis, have ranged from 1.1% to 18.5% [3], with even larger percentages for higher-risk 
subpopulations [4,5]. Long-term outcomes of patients diagnosed with NASH include diabetes, 
cardiovascular disease, cirrhosis, hepatocellular carcinoma, and death [6,7]. 
 Magnetic resonance imaging (MRI)-estimated proton density fat fraction (PDFF) is a 
non-invasive biomarker of hepatic steatosis, which is a key feature of NAFLD and NASH [8]. In 
single-site cross-sectional studies, PDFF has been shown to be accurate using magnetic 
resonance spectroscopy (MRS) as a reference standard [9,10,11,12], and to be reproducible 
across scanner manufacturers and field strengths [13,14]. Moreover, other single-center cross-
sectional studies using liver biopsy as reference have shown that PDFF correlates with hepatic 
steatosis grade [15,16,17,18,19], and accurately classifies dichotomized steatosis grade with 
areas under receiver operating characteristic (ROC) curves ranging from 0.825 to 0.989 [15,20]. 
The performance of PDFF as a biomarker for hepatic steatosis has also been investigated in 
single-center longitudinal treatment trials. In the MOZART trial (35 subjects, diagnosed NASH, 
treated with ezetimibe vs placebo for 24 weeks), histologic responders (reduction in NAFLD 
Activity Score [NAS] of two or more points) had greater relative PDFF reduction (29.3%) than 
non-responders (2.0%) [21]. In another randomized trial (34 subjects, diagnosed NASH, treated 
with N-3 fish oil vs placebo for one year), subjects treated with N3 lost more weight and showed 
a greater decrease in PDFF than those treated with placebo, although there were no differences in 
histologic response [22]. Until now, however, diagnostic performance of PDFF has not been 
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investigated in a well-controlled, multi-center treatment trial. Assessing multi-center diagnostic 
performance is necessary to further validate PDFF prior to its widespread adoption and 
implementation [20]. 
 Therefore, the purpose of this study was to assess cross-sectional and longitudinal 
diagnostic performance of PDFF to grade hepatic steatosis in adults using centrally-scored 
histology as reference. To do this, we performed a prospectively-designed study of PDFF 
estimated by MRI in the Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment 
(FLINT) trial [23]. The FLINT trial was a multi-center, randomized, double-masked, placebo-
controlled, phase 2b clinical trial of treatment with either obeticholic acid or placebo in patients 
with NASH. Hepatic steatosis was assessed at baseline and after 72 weeks of obeticholic acid vs 
placebo by both liver biopsy and MRI, allowing comparison of PDFF to histologic hepatic 
steatosis grade in a well-characterized, longitudinal multi-center study. 
MATERIALS AND METHODS 
Study design 
 MRI was offered at baseline and end-of-treatment (EOT) to adults participating in the 
FLINT trial. PDFF was a secondary imaging endpoint, for which histologic hepatic steatosis 
grade served as the reference standard. 
 Eligibility criteria for the FLINT trial are published elsewhere [23]; all subjects were 
diagnosed with NASH based on local histology review of a standard-of-care liver biopsy. 
Inclusion criteria for the liver MRI portion of the FLINT trial were that the subject was enrolled, 
and that the subject was willing and able to complete both MRI exams (the baseline exam prior 
to randomization and within 90 days of baseline biopsy, and the EOT MRI exam within 90 days 
of EOT biopsy). MRI exclusion criteria were contraindication to MRI, extreme claustrophobia, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
pregnancy or trying to become pregnant, weight or girth exceeding MRI scanner capability, or 
any condition or circumstance that, in the opinion of the clinical trial site investigator would 
interfere with completion of the MRI exam. 
 The FLINT trial, including the MRI portion, was approved by an Institutional Review 
Board at each participating clinical trial site, and was in compliance with the Health Insurance 
Portability and Accountability Act. All subjects enrolled in the FLINT trial signed informed 
consent for MRI exams. 
 All authors had access to the study data and have reviewed and approved the final 
manuscript. 
MRI clinical trial site qualification 
 The MRI portion of this study was managed by the NASH CRN Radiology Coordinating 
Center (RCC) in conjunction with the NASH CRN Data Coordinating Center (DCC). The RCC 
ensured that each participating clinical trial site was qualified to participate in the MRI portion of 
the FLINT trial based on submission of technically adequate phantom or volunteer MRI data, 
and provided central imaging quality control. 
MRI exams 
 Seven of the eight participating FLINT clinical trial sites contributed MRI data to this 
study using 1.5T (three sites) and 3T (four sites) MR scanners (Table 1). At each clinical trial 
site, only a single scanner was used so that longitudinal instrument-dependent measurement 
variability would be minimized. PDFF reproducibility has been demonstrated in two studies 
across different clinical trial sites, and for both field strengths used in this study [13,14]. 
 For each MRI exam, an advanced, non-contrast, breath-hold, magnitude-based, gradient-
recalled-echo (GRE), two-dimensional axial sequence was obtained of the entire liver using a 
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torso array coil centered over the liver. T1 effects that could cause subject- or scanner-dependent 
bias were minimized using a low flip angle (ten degrees) and a repetition time (TR) of ≥ 120 ms. 
Six echoes were collected at alternately out-of-phase and in-phase echo times (TEs) for the water 
and main fat peaks to permit PDFF quantification while accounting for subject-based T2* effects 
[9,10,11,12] (Table 1). Images in Digital Imaging and Communications in Medicine (DICOM) 
format were transferred from clinical trial sites to the RCC for analysis. 
MRI analysis 
 Data analysts at the RCC placed one circular 1-cm radius region of interest (ROI) on 5th 
echo (out-of-phase) images in each of the nine anatomical liver segments; those ROIs were 
propagated to images for the other echoes. Mean signal intensities at those ROI locations were 
recorded. A custom MATLAB™ (The MathWorks, Natick, MA, USA) multi-peak, non-linear, 
least-squares fitting algorithm [9,10,11,12] that accounted for T2* signal decay and multi-
frequency interference effects of the various proton locations in triglyceride [24] was used to 
estimate PDFF for each ROI location. 
Liver biopsy 
 Percutaneous core liver biopsies were performed by NASH CRN investigators as 
research procedures or for clinical care. Hematoxylin and eosin (H&E), Masson's trichrome, and 
iron stains were prepared from formalin-fixed tissue specimens. The interval between 
performance of MRI and biopsy was calculated. Local clinical trial site histological analysis was 
performed to determine eligibility for FLINT trial enrollment; those local scores were not used in 
the current analysis. 
Comparison of histologic steatosis grade and PDFF 
 PDFF, and histologic steatosis percentage (and grade) both assess liver fat, but they do so 
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in very different ways. Histologic steatosis assessment yields a percentage of hepatocytes that 
show fat globules on H&E stain (from whence is derived a steatosis grade from 0 to 3), whereas 
PDFF estimates a ratio of observable MRI signal from fat, compared to all observable MRI 
signal (from both fat and water). Thus, if all examined hepatocytes were seen to be filled with 
50% fat globules, the histologic steatosis percentage would be 100% since all cells show fat 
globules, and the steatosis grade would be 3, but the MRI PDFF percentage would be, ignoring 
technical factors for the moment, something like 50%. Thus, we see in practice that PDFF 
percentages typically are somewhat less than half of histologic steatosis percentages. 
Central histological analysis 
 Biopsies were reviewed by the pathologists of the NASH CRN Pathology Committee 
who provided central histology assessment by consensus at a multi-head microscope. 
Pathologists were blinded to all clinical information, including participation in this study. 
Steatosis grade was provided according to the standardized NASH CRN histological NAFLD 
scoring system (proportion of hepatocytes containing fat macrovesicles: grade 0 for < 5%, grade 
1 for 5 to 33%, grade 2 for > 33 to 66%, and grade 3 for > 66% [25]). Other centrally scored 
features that were evaluated in this study were lobular inflammation, portal inflammation, 
hepatocellular ballooning, fibrosis stage, and NAFLD Activity Score (NAS). 
Blinding 
 RCC analysts and other staff at the RCC were blinded to histology results, and 
pathologists were blinded to imaging results. RCC analysts were blinded to treatment 
assignment. 
Other data 
 Subject demographics, laboratory, anthropomorphic measurements, and medical history 
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were collected at each clinical trial site. 
Statistical analysis 
 Statistical analyses were done with SAS (SAS Institute 2011, Base SAS 9·3 Procedures 
Guide) and Stata (StataCorp 2013, Stata Statistical Software: release 13). 
A single PDFF value was calculated for each MRI exam as the mean of the PDFF values 
for the nine anatomical liver segments. Demographic, histologic and imaging information were 
summarized with categorical variables expressed as numbers and percentages and continuous 
variables expressed by mean (± standard deviation [SD]). The proportion of subjects who had, vs 
did not have MRIs at baseline was compared with regard to treatment group, study site, 
demographics, liver enzymes, lipids, metabolic factors, co-morbidities, concomitant liver 
medications, and histology findings. Pearson partial correlation coefficients and 95% confidence 
intervals were estimated between PDFF and histologic variables (steatosis, lobular inflammation, 
hepatocellular ballooning, fibrosis, and portal inflammation) at baseline and for changes from 
baseline to 72 weeks. 
Diagnostic accuracy of PDFF to classify hepatic steatosis grade at baseline was tested for 
grades 0-1 vs 2-3, and grades 0-2 vs 3. Diagnostic accuracy of change in PDFF to classify 
change in hepatic steatosis grade from baseline to EOT was tested for: reduction vs no 
change/increase and increase vs no change/decrease. Cross-validated area under ROC (AUROC) 
curves using a jack-knife procedure and 95% CIs were estimated for each of these 
dichotomizations [26]. Cut-off PDFF values were estimated using the lowest threshold value for 
which there was ≥ 90% specificity to distinguish between these dichotomized categories. 
Sensitivity, positive predictive values (PPVs), and negative predictive valves (NPVs) were 
calculated along with 95% confidence intervals (CIs) fixing specificity at 90%. 
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RESULTS 
 Of 283 adults enrolled in the FLINT trial from March 16, 2011 to December 3, 2012 at 
eight participating FLINT clinical trial sites, 113 (40%) had MRI and liver biopsy at baseline, 85 
(30%) had MRI and liver biopsy at EOT, and 78 (28%) had MRI and liver biopsy at both time 
points. One subject with a baseline MRI but without a centrally-read baseline liver biopsy was 
excluded from the analysis. All baseline MRIs were performed prior to randomization and 
occurred an average of 51 days following baseline biopsy. Follow-up MRIs were performed an 
average of two days after follow-up biopsy, and were performed from 29 days before to 78 days 
after biopsy. 
 Cohort baseline population characteristics are summarized in Table 2. Subjects who had, 
vs did not have MRIs had significantly (p < 0.05) lower mean aspartate aminotransferase, 
alkaline phosphatase, weight, BMI and prevalence of hyperlipidemia and hypertension. 
Additionally, the 78 subjects with both paired MRIs and paired biopsies vs the 204 subjects 
without, had lower (p < 0.05) mean AST, ALT and alkaline phosphatase at baseline. 
Cross-sectional analysis 
 The distribution of PDFF at baseline is shown in Figure 1: PDFF mean was 
18.6%±9.6%, and ranged from 3.7% to 49.3%. 
 At baseline, 34% (38/113) of biopsies had steatosis grade 0 or 1, 39% (44/113) had 
grade 2, and 27% (31/113) had grade 3 with corresponding mean PDFF values of 9.8%±3.7%, 
18.1%±4.3%, and 30.1%±8.1%, respectively. PDFF values for each histologic steatosis grade at 
baseline are shown in Figure 2. Higher steatosis grade corresponded to higher mean PDFF. 
Partial correlation of baseline PDFF values with histologic features is summarized in 
Table 3. PDFF is highly correlated with steatosis controlling for other histologic features 
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(Pearson Partial Correlation = 0.80 [95% CI, 0.73–0.86]; p < 0.001). 
 Diagnostic accuracy of PDFF for classifying steatosis is summarized in Table 4. The area 
under ROC (AUROC) from logistic regression using PDFF as a surrogate for classifying 
steatosis grade 0-1 vs 2-3 was 0.95 (95% CI, 0.91–0.98) and for classifying steatosis grade 0-2 vs 
3 was 0.96 (95 % CI, 0.93–0.99). PDFF cut-off values at 90% specificity were 16.3% for grades 
2-3, and 21.7% for grade 3 discrimination. Diagnostic accuracy of PDFF for classifying steatosis 
was similar between the 1.5T vs. 3T scanners (data not shown). 
Longitudinal analysis 
 PDFF values for each histologic hepatic steatosis grade change category (reduction, no 
change, and increase in steatosis grade) are shown in the box plots in Figure 3. Changes in 
PDFF were positive in 71% (5/7) of subjects in whom steatosis grade increased and were 
negative in of subjects in 91% (30/33) of subjects in whom steatosis grade decreased. The mean 
(SD) change in MRI-PDFF in 38 subjects with no change in histology grade category was 
0.3%±6.3%, ranging from -21.1 to +21.0%. 
Correlation of change from baseline to EOT in PDFF values with change from baseline to 
EOT in histologic features is summarized in Table 3. Correlation between change in PDFF and 
change in histologic steatosis grade controlling for other histologic features was high (Pearson 
Partial Correlation = 0.63 [95% CI, 0.47–0,75]; p < 0.001). 
 Diagnostic accuracy of change in PDFF vs change in histologic hepatic steatosis grade 
from baseline to EOT is summarized in Table 4. At EOT, 42% of paired biopsies had 
improvement in steatosis grade, 49% had no change, and 9% had worsening. The AUROC using 
PDFF change to classify histologic hepatic steatosis grade improvement and worsening, 
respectively, were 0.81 (95% CI, 0.71–0.91) and 0.81 (95% CI, 0.63–0.99). Cut-off values for 
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PDFF change at 90% specificity were -5.1% for improvement and +5.6% for worsening hepatic 
steatosis grade. 
DISCUSSION 
 We compared PDFF to histologic hepatic steatosis grade at baseline, and change in PDFF 
to change in histologic hepatic steatosis grade from baseline to EOT. We found that PDFF 
correlates well with histologic hepatic steatosis grade cross-sectionally, and that change in PDFF 
correlates well with change in histologic hepatic steatosis grade longitudinally. 
 ROC analysis at baseline yielded PDFF cutoffs predicting histologic hepatic steatosis 
grade that are similar to those reported in the literature for a single-center study. We found that at 
90% specificity, PDFF cut-off values were 16.3% (83% sensitivity) and 21.7% (84% sensitivity) 
for discrimination of histologic steatosis grades 0-1 from 2-3, and grades 0-2 from 3, 
respectively. Tang et al [15] reported PDFF cut-off values for those discriminations in their 
single-center study of 77 children and adults with known or suspected NAFLD of 17.4% (64% 
sensitivity and 96% specificity) and 22.1% (71% sensitivity and 92% specificity), respectively. 
In a subsequent single-center study of 89 adults, Tang et al [27] subsequently reported high 
sensitivity and specificity for those cutoffs to distinguish steatosis grades in another clinical trial. 
As emphasized previously by others [28], PDFF is a quantitative marker of MRI-visible fat 
content while histology scoring is a semi-quantitative marker of proportion of steatotic 
hepatocytes. Since PDFF and histology do not attempt to measure the same quantity, perfect 
agreement is not expected. 
 The AUROC of PDFF for classifying longitudinal change in steatosis is 0.81, which is 
inferior to its cross-sectional performance at baseline. The lower AUROC for change may reflect 
the 'noisiness' of histologic grading as a marker of steatosis, an effect which is amplified when 
differences in PDFF are compared to differences in histologic steatosis grade. 
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 Hepatic steatosis may also be assessed non-invasively by CAP (a transient elastography-
derived controlled attenuation parameter), which is an estimate of total ultrasound attenuation 
[29]. Although we did not perform a direct comparison of CAP and PDFF, the accuracy of MRI 
to estimate PDFF has been reported to be higher than that of CAP, using histology as reference 
standard [30 31]. 
 Strengths of this study are that the cohort of patients that was studied was well-
characterized, with a racial/ethnic makeup representative of patients diagnosed with NASH in 
the United States; that subjects enrolled in this study had both pre- and post-treatment biopsy; 
that histology was scored centrally by the NASH CRN Pathology Committee; and that a range of 
MRI scanner manufacturers at two field strengths and across multiple study sites were utilized. 
Thus, our study results are likely to be generalizable to the entire adult NASH population in the 
United States, while also providing compelling evidence that MRI-PDFF can be applied 
successfully in multi-center trials. 
A major limitation of this study was that not all subjects enrolled in the FLINT trial had 
MRIs. Only 40% of randomized subjects had an MRI at baseline and only 28% had paired EOT 
and baseline MRIs. Participation in the MRI study was reduced because the MRI qualification 
process at each clinic was completed after the start of enrollment into the trial. Participation rates 
into the MRI study varied widely at the nine study sites, ranging from 0 to 84%. In addition, 
subjects who had the MRI weighed significantly less than those who did not participate; this may 
be because the heaviest FLINT participants were too large to undergo MRI. Also, significantly 
lower mean alanine aminotransferase and aspartate aminotransferase and lower rates of 
hyperlipidemia and hypertension were seen at baseline in those who did vs did not participate in 
the MRI study suggesting a less severe group in those who participated. Our results could be 
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biased if the relationships between MRI-PDFF and histologic features varied in those who 
participated vs did not participate in the MRI study. 
 Another limitation was that relatively few subjects of non-White race were included. This 
was unavoidable since NASH is relatively uncommon in non-Whites, and the racial and ethnic 
diversity of our study population reflects that seen in the national prevalence of NASH. Our 
study also did not include children, as the FLINT trial enrolled only adults; thus multi-center 
validation studies of MRI PDFF in children are needed. Finally, potentially confounding factors 
such as those in Table 2 were not investigated because the study was not powered to permit 
those investigations. It is also not likely that there are meaningful confounders to our results, 
given that none have been reported for single-site studies [14,15]. 
Steatosis grade was determined in this study according to the standardized NASH CRN 
histological NAFLD scoring system based on the proportion of hepatocytes containing fat 
macrovesicles. The performance of MRI PDFF compared to microvesicular steatosis remains 
unclear, especially since microvesicular steatosis is often under-staged. The relationship of 
microvesicular steatosis and PDFF was not examined in this paper because all work to date 
validating MRI PDFF against MR spectroscopy and histology has considered only 
macrovesicular steatosis, and because microvesicular steatosis is an uncommon finding in NASH 
tending to be seen in the more severe cases [32]. 
Finally, since an inclusion criterion for the FLINT trial was the presence of NASH as 
assessed by a local pathologist, only one subject had histologic hepatic steatosis grade 0 at 
central reading. Hence, grades 0 and 1 were considered as a single category in our analyses. 
Further multi-center studies in populations including subjects with lower amounts of hepatic 
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steatosis (i.e., grades 0 and 1) are needed to investigate correlations of PDFF with hepatic 
steatosis in that range. 
 In conclusion, in a well-controlled, multi-center study in adults, PDFF showed high 
agreement with histologic hepatic steatosis grade based on MRI data at sites using scanners from 
different manufacturers and of different field strengths. Importantly, change in PDFF accurately 
classified change in EOT histologic hepatic steatosis grade. These findings support wider use of 
PDFF in multi-center trials in adults as a biomarker for hepatic steatosis at baseline, and for 
change in hepatic steatosis with treatment. 
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FIGURE CAPTIONS 
Figure 1. PDFF distribution of study population at baseline. 
Figure 2. Bar and whisker plot at baseline of PDFF vs steatosis grade. For each steatosis 
grade, maximum and minimum PDFF values are indicated by horizontal lines at 
the bottom and top of each steatosis grade entry, the darkened box in the middle 
represents PDFF data points in the 25% to 75% interquartile range, and the line 
through the middle of the central darkened box represents the median PDFF 
value. 
Figure 3. Bar and whisker plot of change in PDFF vs change in histologic hepatic steatosis 
grade. Mean PDFF change values for steatosis grade reduction, no change in 
steatosis grade , and increase in steatosis grade were, respectively: -7.4%± 8.7% 
(n=42), 0.3%±6.3% (n=49), and 7.7%± 6.0% (n=9). Explanations of each bar-
and-whisker plot entry are as noted for Figure 2, except that in this figure values 
represent PDFF change, the maximum and minimum PDFF change values that are 
indicated by horizontal lines at the bottom and top of each steatosis grade entry 
exclude outliers, and the isolated dots represent outliers. 
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TABLES 
Table 1. MRI scanners and techniques 
 
 
  
Clinical trial site MR scanners 1.5T 3T 
Site A - Siemens TIM Trio 
Site B - Siemens TIM Trio 
Site C Siemens Avanto - 
Site D - GE Signa HDxt 
Site E - GE Signa HDxt 
Site F Siemens Avanto - 
Site G Siemens TIM Symphony - 
   
Scanning parameters   
Repetition time (ms) ≥ 120 ≥ 120 
First time-to-echo (ms) 2.3 1.15 
Delta time-to-echo (ms) 2.3 1.15 
Number of echoes 6 6 
Flip angle (°) 10 10 
Bandwidth (Hz/Px) ≥ 500 ≥ 1,000 
Slice thickness (mm) 8 or 10 8 or 10 
Slice gap (mm) 0 0 
Phase encoding steps 192 128 
Frequency encoding steps 192 128 
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Table 2. Baseline characteristics of those obtaining vs not obtaining baseline MRI 
 
 Baseline 
MRI 
(n=113) 
No 
Baseline 
MRI 
(n=169) 
p-value 
Study site* – no. 
Site A 14 15 
 
Site B 15 12 
 
Site C 17 10 
 
Site D 32 6 
 
Site E 7 21 
 
Site F 9 33 
 
Site G 19 18 
 
Treatment group 
Obeticholic acid – no. (%) 55 (48.7) 86 (50.9) 0.81 
Demographics 
Age (yrs) 51±11 51±11 0.98 
Male sex - no. (%) 43 (38.0) 53 (31.2) 0.25 
White race - no. (%) 93 (82.3) 140 (82.8) 1.00 
Hispanic ethnicity - no. (%) 19 (16.8) 24 (14.2) 0.61 
Liver enzymes 
Aspartate aminotransferase - U/L 55±32 65±39 0.03 
Alanine aminotransferase – U/L 76±43 87±54 0.08 
γ-Glutamyltransferase – U/L 80±115 75±71 0.71 
Alkaline phosphatase - U/L 78±26 85±27 0.03 
Total bilirubin – mg/dL 0.6±0.3 0.7±0.4 0.49 
Metabolic factors 
Weight - kg 95±17 100±23 0.03 
Body-mass index - kg/m2 33.6±5.2 35.3±6.9 0.02 
Waist circumference - cm 109±12 112±16 0.16 
Waist to hip ratio 0.95±0.07 0.95±0.09 0.99 
Fasting serum glucose - mg/dL 113±31 118±40 0.19 
Insulin - umol/mL 28±36 28±27 0.94 
HOMA-IR - (mg/dL * umol/mL) / 405 8.5±12.1 8.3±8.7 0.90 
Hemoglobin A1c - % 6.3±1.0 6.6±1.1 0.06 
Systolic blood pressure - mmHg 130±16 133±16 0.15 
Diastolic blood pressure - mmHg 78±11 77±10 0.64 
Comorbidities 
Hyperlipidemia - no. (%) 58 (51.3) 115 (68.0) 0.006 
Hypertension - no. (%) 59 (52.2) 112 (66.3) 0.02 
Diabetes - no. (%) 57 (50.4) 92 (54.4) 0.54 
Cardiovascular disease - no. (%) 4 (3.5) 11 (6.5) 0.42 
Liver histology findings 
Definite steatohepatitis - no. (%) 91 (80.5) 134 (79.3) 0.88 
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Fibrosis - stage1 1.7±1.1 1.9±1.0 0.23 
NAFLD activity score (NAS)2 5.2±1.3 5.2±1.3 0.62 
    Hepatocellular ballooning - score 1.4±0.7 1.4±0.8 0.88 
    Steatosis - score 1.9±0.8 2.1±0.8 0.08 
    Lobular inflammation - score 1.8±0.7 1.8±0.7 0.34 
Portal inflammation - score3 1.1±0.6 1.2±0.6 0.86 
Notes: Plus-minus values are means±SD; BMI = body mass index; PDFF = proton density fat 
fraction; SD = standard deviation. 
* Two study sites with combined 55 randomized subjects did not obtain MRIs 
1 Fibrosis was assessed on a scale of 0 to 4, with higher scores indicating more severe 
fibrosis 
2 NAS was assessed on a scale of 0 to 8, with higher scores indicating more severe disease; 
the components of this measure are steatosis (assessed on a scale of 0 to 3), lobular 
inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on a 
scale of 0 to 2) 
3 Portal inflammation was assessed on a scale of 0 to 2 with higher scores indicating more 
severe inflammation 
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Table 3. Partial correlation of MRI-PDFF with histologic components at baseline and 
change in MRI-PDFF with change in histologic components at EOT 
 
Histologic component MRI-PDFF at baseline 
(n=113) 
Change in MRI-PDFF at EOT 
(n=78) 
 
r 95% CI p-value r 95% CI p-value 
Steatosis 0.80 0.80–0.90 < 0.001 0.63 0.47–0.75 < 0.001 
Lobular inflammation -0.21 -0.28–0.09 0.03 -0.14 -0.36–0.09 0.23 
Ballooning -0.02 -0.51–-0.19 0.85 0.17 -0.06–0.39 0.14 
Fibrosis -0.11 -0.47–-0.14 0.24 -0.18 -0.39–0.05 0.13 
Portal inflammation 0.02 -0.30–0.07 0.84 -0.13 -0.35–0.10 0.26 
Notes: MRI = magnetic resonance imaging; PDFF = proton density fat fraction; EOT = end of 
treatment 
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Table 4. Diagnostic accuracy of PDFF for classifying steatosis 
 
Cross-
sectional 
steatosis 
grade 
classification 
(n=113) 
MRI PDFF threshold 
(%) at 90% 
specificity 
Sensitivity PPV NPV AUROC 
(95% CI) 
0-1 vs 2-3 16.3 83% 
(62/75) 
95% 
(62/65) 
73% 
(35/48) 
0.95 (0.91–
0.98) 
0-2 vs 3 21.7 84% 
(26/31) 
76% 
(26/34) 
94% 
(74/79) 
0.96 (0.93–
0.99) 
 
Longitudinal 
steatosis 
grade change 
classification 
(n=78) 
Mean 
(SD) 
PDFF 
change 
(%) 
Cutoff 
PDFF 
change at 
90% 
specificity 
(%) 
Sensitivity PPV NPV AUROC 
(95% CI) 
Decrease in 
steatosis grade 
(improvement) 
(42%) 
-7.4±8.7 - 5.1 58% 
(19/33) 
83% 
(19/23) 
75% 
(41/55) 
0.81 (0.71–
0.91) 
No change in 
steatosis grade 
(49%) 
0.3±6.3 - - - - - 
Increase in 
steatosis grade 
(worsening) 
(9%) 
7.7±6.0 5.6 57% (4/7) 36% (4/11) 96% 
(64/67) 
0.81 (0.63–
0.99) 
Notes: PDFF = proton density fat fraction; MRI = magnetic resonance imaging; PPV = positive 
predictive value; NPV = negative predictive value; AUROC = area under ROC curve; CI = 
confidence interval 
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